logo-loader
RNS
viewTissue Regenix Group PLC

Appointment of CFO

/**/ sup{font-size:80%}link{ color: #000000 }visited{ color: fuchsia } .m{size:595.0pt 842.0pt;margin:72.0pt 72.0pt 72.0pt 72.0pt;}div.m{}p.ar{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";color:black;border:none;font-weight: bold; line-height: 115%; margin-bottom: 0cm; text-align: center}p.as{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";color:black;border:none;line-height: 115%; margin-bottom: 0cm; text-align: center}p.at{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";color:black;border:none;margin-bottom:0cm;margin-bottom:.0001pt;text-align:justify; text-justify:inter-ideograph;line-height:115%}p.au{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";color:black;border:none;font-weight: bold; line-height: 115%; margin-bottom: 0cm}p.av{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";color:black;border:none;margin-bottom:0cm;margin-bottom:.0001pt;line-height:115%}table.aw{margin-left:1.5pt;border-collapse:collapse;border:none}tr.ah{height:26.05pt}td.aj{width:263.05pt;border:none;border-bottom: solid black 1.0pt;padding:4.0pt 4.0pt 4.0pt 4.0pt;height:26.05pt} p.ax{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";color:black;border:none;margin-bottom:0cm;margin-bottom:.0001pt;line-height: 115%}td.ai{width:166.85pt;border:none;border-bottom: solid black 1.0pt;padding:4.0pt 4.0pt 4.0pt 4.0pt;height:26.05pt}tr.ae{height:12.25pt}td.ag{width:263.05pt;border:none;padding:4.0pt 4.0pt 4.0pt 4.0pt; height:12.25pt}p.a,li.a,div.a{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";border:none;}td.af{width:166.85pt;border:none;padding:4.0pt 4.0pt 4.0pt 4.0pt; height:12.25pt}tr.ab{height:39.85pt}td.ad{width:263.05pt;border:none;border-bottom: solid black 1.0pt;padding:4.0pt 4.0pt 4.0pt 4.0pt;height:39.85pt}td.ac{width:166.85pt;border:none;border-bottom: solid black 1.0pt;padding:4.0pt 4.0pt 4.0pt 4.0pt;height:39.85pt}tr.y{height:12.5pt} td.aa{width:263.05pt;border:none;border-bottom: solid black 1.0pt;padding:4.0pt 4.0pt 4.0pt 4.0pt;height:12.5pt}td.z{width:166.85pt;border:none;border-bottom: solid black 1.0pt;padding:4.0pt 4.0pt 4.0pt 4.0pt;height:12.5pt}tr.v{height:40.2pt}td.x{width:263.05pt;border:none;border-bottom: solid #D7D7D7 1.0pt;padding:4.0pt 4.0pt 4.0pt 4.0pt;height:40.2pt}td.w{width:166.85pt;border:none;border-bottom: solid #D7D7D7 1.0pt;padding:4.0pt 4.0pt 4.0pt 4.0pt;height:40.2pt}p.ay{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";color:black;border:none;margin-top:0cm;margin-right:0cm;margin-bottom:0cm; margin-left:.1pt;margin-bottom:.0001pt;text-indent:-.1pt;line-height:normal}p.az{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";color:black;border:none;font-weight: bold; line-height: 115%; margin-bottom: 0cm; text-align: justify; text-justify: inter-ideograph}table.ba{margin-left:-5.4pt;border-collapse:collapse}td.q{width:214.45pt;padding:0cm 5.4pt 0cm 5.4pt}p.bb{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";color:black;border:none;border: none; font-weight: bold; line-height: 115%; margin-bottom: 0cm; text-align: justify; text-justify: inter-ideograph} p.bc{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";color:black;border:none;margin-bottom:0cm;margin-bottom:.0001pt;text-align:justify; text-justify:inter-ideograph;line-height:115%;border:none}p.bd{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";color:black;border:none;font-div: italic; line-height: 115%; margin-bottom: 0cm}p.i,li.i,div.i{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";color:black;border:none;} /**/
RNS Number : 3280K
Tissue Regenix Group PLC
28 August 2019
 

Tissue Regenix Group plc

 

Appointment of CFO

 

Leeds, 28 August 2019 - Tissue Regenix Group (AIM:TRX) ("Tissue Regenix" or the "Group"), the regenerative medical devices company, announces the appointment of Mike Barker as Chief Financial Officer (CFO).  Mike will join the Group as CFO and as an Executive Director on the Board with immediate effect having supported Tissue Regenix since the beginning of the year as interim Finance Director. 

 

A Chartered Accountant for over 20 years, Mike has experience of both AIM listed and private businesses. After training with Deloitte, he spent 10 years in their corporate finance advisory business working extensively on private equity transactions before setting up his own consultancy business to assist SME's in the delivery of their strategic plans. During this time, he worked closely with the management team of Quantum Pharma plc, a UK manufacturer and supplier of unlicensed medicines and hard-to-source products (acquired by Clinigen Group plc in 2017), to deliver strategic projects before holding the position of Group Corporate Development Director.

 

Full details of Mike's current and past directorships are provided below.  

 

John Samuel, Executive Chairman, Tissue Regenix Group plc, commented: 

"It's a pleasure to welcome Mike to the Executive team. He is well acquainted with the business, having supported the Group since the beginning of the year. His experience in AIM listed businesses and contribution to strategic planning will augment and strengthen our management and Executive teams as we continue to improve the efficiency of our operations across the business to meet the increasing demand for our products."

 

For more information:

 

Tissue Regenix Group plc

Caitlin Pearson, Head of Communications  

Tel: 0330 430 3073 / 07920272441



Stifel Nicolaus Europe Limited (Nominated Adviser and Broker)

Jonathan Senior / Alex Price / Ben Maddison

Tel:  0207 710 7600

 



FTI Consulting 

Brett Pollard / Victoria Foster Mitchell / Mary Whittow

Tel: 0203 727 1000

 

 

 

 

Regulatory disclosures

 

Michael (Mike) Denis Barker, aged 43 

 

Current directorships:

Directorships in the last 5 years:

TimeC 1306 Limited

Quantum Pharma Group Limited

Barker Advisory Limited

Quantum Pharmaceutical Limited

Rhythm Time (Newcastle) LLP

Nupharm Laboratories Limited

Cambridge Scholars Publishing Ltd

Nupharm Group Limited

Ridge Pharma Ltd

 


There is no further information to be disclosed in accordance with the requirements of Schedule Two paragraph (g) of the AIM rules.

 

About Tissue Regenix

Tissue Regenix is a leading medical devices company in the field of regenerative medicine. Tissue Regenix was formed in 2006 when it was spun-out from the University of Leeds, UK. The company's patented decellularisation ('dCELL®') technology removes DNA and other cellular material from animal and human soft tissue leaving an acellular tissue scaffold which is not rejected by the patient's body and can then be used to repair diseased or worn out body parts. Current applications address many critical clinical needs such as sports medicine, heart valve replacement and wound care.

 

In November 2012 Tissue Regenix Group plc set up a subsidiary company in the United States - 'Tissue Regenix Wound Care Inc.', January 2016 saw the establishment of joint venture GBM-V, a multi- tissue bank based in Rostock, Germany.

 

In August 2017 Tissue Regenix acquired CellRight Technologies®, a biotech company that specializes in regenerative medicine and is dedicated to the development of innovative osteoinductive and wound care scaffolds that enhance healing opportunities of defects created by trauma and disease. CellRight's human osteobiologics may be used in spine, trauma, general orthopedic, foot & ankle, dental, and sports medicine surgical procedures.

 

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
BOAPGUWWRUPBGRM

Quick facts: Tissue Regenix Group PLC

Price: 1.1266

Market: AIM
Market Cap: £13.2 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Tissue Regenix "advancing on many fronts" says CEO after SurgiPure FDA clearance

Antony Odell, chief executive at Tissue Regenix (LON:TRX), talks to Proactive Investors about the US FDA clearance for SurgiPure XD, a skin graft for hernias derived from pig tissue. The group, which already has experience of commercialising products in the US, is planning a commercial...

on 03/09/2016

RNS

Directorate Change

2 days, 20 hours ago

Holding(s) in Company

6 days, 20 hours ago

Holding(s) in Company

1 week, 1 day ago

Holding(s) in Company

1 week, 1 day ago

Second Price Monitoring Extn

1 week, 3 days ago

Price Monitoring Extension

1 week, 3 days ago